About

Hemophilia A is a genetic disorder that impairs blood clotting due to a deficiency in factor VIII, leading to frequent and severe bleeding episodes. Denecimig is a bispecific antibody designed to mimic the function of factor VIII, helping the blood clot more effectively. By acting as a substitute for the missing protein, it may reduce the risk of bleeding and improve quality of life for those with hemophilia A.